COMMUNIQUÉS West-GlobeNewswire

-
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
07/07/2025 -
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
07/07/2025 -
ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison, PhD to its Board of Directors
07/07/2025 -
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
07/07/2025 -
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
07/07/2025 -
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
07/07/2025 -
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health
07/07/2025 -
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
04/07/2025 -
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/07/2025 -
Monthly information on share capital and company voting rights
04/07/2025 -
Seule la transparence et la responsabilité peuvent sauver le CERN : une condition essentielle pour mettre fin au gaspillage de milliards et accélérer les innovations médicales vitales
04/07/2025 -
The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice
04/07/2025 -
Virbac : Déclaration d'actions et de droits de vote 06/2025
04/07/2025 -
Virbac : Declaration of the number of shares and voting rights 06/2025
04/07/2025 -
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions
04/07/2025 -
Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025
04/07/2025 -
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
04/07/2025 -
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
04/07/2025 -
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
04/07/2025
Pages